#rare diseases
Related Stories (4)
Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder - Reuters
Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder Reuters
August 19, 2026Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug - Reuters
Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug Reuters
August 12, 2026Vertex to buy Crinetics for $10 billion in rare-diseases push - Reuters
Vertex to buy Crinetics for $10 billion in rare-diseases push Reuters
July 6, 2026FDA vaccines chief Vinay Prasad to leave regulator in April - Reuters
FDA vaccines chief Vinay Prasad to leave regulator in April Reuters
March 6, 2026Related Pages (3)
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
FDA vaccines chief who ran afoul of pharma to depart
Vinay Prasad, the Trump administration regulator who angered pharma companies and crushed the hopes of patients with rare diseases with a series of controversial decisions to reject new drug applicati